Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinwei Guben Formula (JWGB), also known as Jinwei Formula II, is a Traditional Chinese Medicine (TCM) formula clinically utilized for the treatment of chronic obstructive pulmonary disease (COPD). Research indicates that JWGB modulates the formation of neutrophil extracellular traps (NETs), which are known to drive chronic inflammation in the airways. Furthermore, the formula enhances the efficacy of glucocorticoids, addressing the steroid resistance often observed in COPD patients. This therapeutic effect is mediated through the regulation of Histone Deacetylase 2 (HDAC2), an enzyme critical for the anti-inflammatory action of corticosteroids that is typically impaired in oxidative stress environments associated with lung disease.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinwei Guben Formula.